Limits...
Sunitinib induced pyoderma gangrenosum-like ulcerations.

Akanay-Diesel S, Hoff NP, Kürle S, Haes J, Erhardt A, Häussinger D, Schulte KW, Bölke E, Matuschek C, Budach W, Gerber PA, Homey B - Eur. J. Med. Res. (2011)

Bottom Line: Pyoderma gangrenosum is a non-infectious neutro?philic skin disease commonly associated with underlying systemic diseases.Solely cessation of sunitinib therapy resulted in an improvement of the ulcerations.Sunitinib is a multikinase inhibitor that targets the PDGF-α- and ?β-, VEGF-1-3-, KIT-, FLT3-, CSF-1- and RET-receptor, thereby impairing tumour proliferation, pathological angiogenesis and metastasation.

View Article: PubMed Central - HTML - PubMed

Affiliation: Universitätsklinikum Düsseldorf, Heinrich Heine Universität, Duesseldorf, Germany.

ABSTRACT
Pyoderma gangrenosum is a non-infectious neutro?philic skin disease commonly associated with underlying systemic diseases. Histopathological and laboratory diagnostics are unspecific in the majority of the cases and the diagnosis is made in accordance with the clinical picture. Here, we report the case of a 69-year old man with progredient pyoderma gangrenosum-like ulcerations under treatment with sunitinib due to hepatocellular carcinoma. A conventional ulcer therapy did not lead to a regression of the lesions. Solely cessation of sunitinib therapy resulted in an improvement of the ulcerations. Sunitinib is a multikinase inhibitor that targets the PDGF-α- and ?β-, VEGF-1-3-, KIT-, FLT3-, CSF-1- and RET-receptor, thereby impairing tumour proliferation, pathological angiogenesis and metastasation. Here, we demonstrate that pyoderma gangrenosum-like ulcers may represent a serious side effect of sunitinib-based anti-cancer treatment.

Show MeSH

Related in: MedlinePlus

Facial erythema and hypopigmentation of hair.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3351806&req=5

Figure 5: Facial erythema and hypopigmentation of hair.

Mentions: Sunitinib is a multikinase-inhibitor, which inhibits the PDGF-α- and -β-, VEGF-1-3-, KIT-, FLT3, CSF1- and RET-receptor, thereby impairing tumour proliferation, pathological angiogenesis and metastazation. Sunitinib is used in the treatment of various tumor entities, such as metastasized renal cell carcinoma, gastrointestinal stroma tumour or HCC [14]. Known side effects of sunitinib include fatigue, diarrhoea, arterial hypertension, hypothyreosis and also cutaneous side effects like stomatitis, hypo- and hyperpigmentation, erythrodysesthesia palmoplantaris, facial edema, subungual hemorrhagia, facial erythema, alopecia and pyoderma gangrenosum-like ulcerations. In our patient we observed hyperpigmentation of the skin (Figure 4), hypopigmentation of the hair as well as facial erythema (Figure 5).


Sunitinib induced pyoderma gangrenosum-like ulcerations.

Akanay-Diesel S, Hoff NP, Kürle S, Haes J, Erhardt A, Häussinger D, Schulte KW, Bölke E, Matuschek C, Budach W, Gerber PA, Homey B - Eur. J. Med. Res. (2011)

Facial erythema and hypopigmentation of hair.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3351806&req=5

Figure 5: Facial erythema and hypopigmentation of hair.
Mentions: Sunitinib is a multikinase-inhibitor, which inhibits the PDGF-α- and -β-, VEGF-1-3-, KIT-, FLT3, CSF1- and RET-receptor, thereby impairing tumour proliferation, pathological angiogenesis and metastazation. Sunitinib is used in the treatment of various tumor entities, such as metastasized renal cell carcinoma, gastrointestinal stroma tumour or HCC [14]. Known side effects of sunitinib include fatigue, diarrhoea, arterial hypertension, hypothyreosis and also cutaneous side effects like stomatitis, hypo- and hyperpigmentation, erythrodysesthesia palmoplantaris, facial edema, subungual hemorrhagia, facial erythema, alopecia and pyoderma gangrenosum-like ulcerations. In our patient we observed hyperpigmentation of the skin (Figure 4), hypopigmentation of the hair as well as facial erythema (Figure 5).

Bottom Line: Pyoderma gangrenosum is a non-infectious neutro?philic skin disease commonly associated with underlying systemic diseases.Solely cessation of sunitinib therapy resulted in an improvement of the ulcerations.Sunitinib is a multikinase inhibitor that targets the PDGF-α- and ?β-, VEGF-1-3-, KIT-, FLT3-, CSF-1- and RET-receptor, thereby impairing tumour proliferation, pathological angiogenesis and metastasation.

View Article: PubMed Central - HTML - PubMed

Affiliation: Universitätsklinikum Düsseldorf, Heinrich Heine Universität, Duesseldorf, Germany.

ABSTRACT
Pyoderma gangrenosum is a non-infectious neutro?philic skin disease commonly associated with underlying systemic diseases. Histopathological and laboratory diagnostics are unspecific in the majority of the cases and the diagnosis is made in accordance with the clinical picture. Here, we report the case of a 69-year old man with progredient pyoderma gangrenosum-like ulcerations under treatment with sunitinib due to hepatocellular carcinoma. A conventional ulcer therapy did not lead to a regression of the lesions. Solely cessation of sunitinib therapy resulted in an improvement of the ulcerations. Sunitinib is a multikinase inhibitor that targets the PDGF-α- and ?β-, VEGF-1-3-, KIT-, FLT3-, CSF-1- and RET-receptor, thereby impairing tumour proliferation, pathological angiogenesis and metastasation. Here, we demonstrate that pyoderma gangrenosum-like ulcers may represent a serious side effect of sunitinib-based anti-cancer treatment.

Show MeSH
Related in: MedlinePlus